Patents Assigned to Futura Medical Developments Limited
-
Patent number: 11376213Abstract: There is described a topical composition for application of an NSAID comprising ibuprofen, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and optionally water, the ingredients of the residual carrier system having the following concentrations in percentages by weight: polyhydric alcohol 50-90 glycol ether 7.5-40 ester 0.5-5 water optional in which either the composition or the residual phase is in a single phase under ambient conditions and the maximum water concentration is that above which the composition or the residual phase exhibits signs of inhomogeneity.Type: GrantFiled: June 7, 2017Date of Patent: July 5, 2022Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventors: Adrian Davis, Marc Barry Brown
-
Patent number: 10028927Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.Type: GrantFiled: February 22, 2016Date of Patent: July 24, 2018Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Davis
-
Patent number: 10004712Abstract: There is provided a condom having a coating or deposit of a composition which includes a physiologically-active agent such as glyceryl trinitrate, wherein the condom has been treated with a neutralising or acidic material such that the condom, when immersed in water, results in the water having a pH of 7 or less. The condom may be treated with an acidic slurry of dusting powder. Also provided is a process for the manufacture of condoms, in which the process includes the steps of: 1) treating the formed condoms with a neutralising or acidic material; and 2) thereafter applying to the condoms a composition including a physiologically-active agent such as glyceryl trinitrate, wherein the condoms, when immersed in water, results in the water having a pH of 7 or less.Type: GrantFiled: March 4, 2014Date of Patent: June 26, 2018Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Bill Potter
-
Publication number: 20180036269Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.Type: ApplicationFiled: February 22, 2016Publication date: February 8, 2018Applicant: Futura Medical Developments LimitedInventor: Adrian DAVIS
-
Patent number: 9358219Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.Type: GrantFiled: November 10, 2010Date of Patent: June 7, 2016Assignee: Futura Medical Developments LimitedInventor: Adrian Francis Davis
-
Patent number: 9265721Abstract: A composition for topical application to a part of the body comprises a local anaesthetic and optionally a vasodilator as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the active ingredient. The vasodilator may comprise glyceryl trinitrate and the local anaesthetic may comprises an anaesthetic of the aminoamide or aminoester type. The volatile solvent may comprise a mixture of water with a C1-C5 alcohol and the non-volatile solvent may comprise a polyhydric alcohol and optionally a glycol. A low-concentration vasodilator-containing composition is also described. The compositions allow a “virtual injection” of the active ingredient to be delivered transdermally without general systemic uptake.Type: GrantFiled: January 23, 2007Date of Patent: February 23, 2016Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Francis Davis
-
Patent number: 8951553Abstract: A composition for topical application to a part of the body comprises a vasodilator, for example glyceryl trinitrate, as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the vasodilator. The vasoldator is present in the composition at a concentration at or slightly below saturation, whereby evaporation of the volatile solvent in use will maintain the vasodilator at saturated or super-saturated concentrations in the residue, whereby the vasodilator will become saturated or supersaturated in the solvent remaining and, as the active ingredient passes through the skin and is absorbed in the bloodstream, and thus becomes depleted in the residual composition, continuing evaporation of volatile solvent will maintain the active ingredient substantially at saturation or supersaturation level in the residual composition throughout the major part of the absorption phase, thereby maximising absorption levels but at a moderate dosage level.Type: GrantFiled: August 8, 2005Date of Patent: February 10, 2015Assignee: Futura Medical Developments Limited Surrey Technology CentreInventor: Adrian Francis Davis
-
Patent number: 8541470Abstract: A composition for topical application of an NSAID comprises a solution or suspension of the NSAID in a carrier system comprising a polyhydric alcohol, a glycol ether and an ester of A higher fatty acid, the carrier system being present as a single phase at ambient temperatures. The NSAID may be diclofenac as diclofenac acid. The polyhydric alcohol may be a glycol such as isopropylene glycol and the glycol ether may be a diethylene glycol ether such as diethylene glycol monoethyl ether.Type: GrantFiled: February 15, 2008Date of Patent: September 24, 2013Assignee: Futura Medical Developments LimitedInventor: Adrian Francis Davis
-
Publication number: 20120248142Abstract: A pharmaceutical composition comprises an active ingredient dissolved in an essentially non-aqueous carrier system comprising volatile and non-volatile components, in which the volatile component comprises a volatile non-solvent for the active ingredient and a volatile solvation additive for the non-solvent and the non-volatile component comprises a non-volatile non-solvent and optionally a non-volatile solvent for the active ingredient, the volatile and non-volatile non-solvents comprising silicone fluids of respectively different viscosity.Type: ApplicationFiled: November 10, 2010Publication date: October 4, 2012Applicant: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Francis Davis
-
Patent number: 6840244Abstract: A condom has an erectogenic compound immobilised on the interior surface and substantially at the head end thereof. The compound may be applied as a component of a composition comprising the erectogenic compound dispersed or dissolved in a gel carrier comprising a liquid medium including a thickening agent. The condom may include a lubricant which may be immiscible with the erectogenic compound or composition. Use of the condom sustains e penile erection following spontaneous initiation thereof, to prevent slippage of the condom off the penis while intercourse takes place.Type: GrantFiled: March 28, 2002Date of Patent: January 11, 2005Assignee: Futura Medical Developments LimitedInventor: Colin Anthony Kemp